Walser Wealth Management Company A Ltd Liability Co Purchases 6,584 Shares of Danaher Corporation $DHR

Walser Wealth Management Company A Ltd Liability Co bought a new stake in Danaher Corporation (NYSE:DHR) in the 3rd quarter, Holdings Channel.com reports. The firm bought 6,584 shares of the conglomerate’s stock, valued at approximately $1,459,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. V Square Quantitative Management LLC lifted its position in Danaher by 6.9% during the third quarter. V Square Quantitative Management LLC now owns 13,696 shares of the conglomerate’s stock worth $3,034,000 after acquiring an additional 884 shares during the last quarter. YANKCOM Partnership boosted its holdings in Danaher by 7.1% in the 3rd quarter. YANKCOM Partnership now owns 1,893 shares of the conglomerate’s stock valued at $419,000 after purchasing an additional 125 shares during the period. Cohen Klingenstein LLC boosted its holdings in Danaher by 227.1% in the 3rd quarter. Cohen Klingenstein LLC now owns 31,400 shares of the conglomerate’s stock valued at $6,957,000 after purchasing an additional 21,800 shares during the period. AdvisorNet Financial Inc grew its position in shares of Danaher by 1,832.9% during the 3rd quarter. AdvisorNet Financial Inc now owns 12,970 shares of the conglomerate’s stock worth $2,874,000 after purchasing an additional 12,299 shares in the last quarter. Finally, Barlow Wealth Partners LLC acquired a new position in shares of Danaher during the 3rd quarter worth approximately $580,000. Institutional investors own 79.05% of the company’s stock.

Key Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery
• Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings

Danaher Trading Up 3.0%

Shares of DHR stock opened at $231.52 on Friday. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The stock’s fifty day moving average price is $213.55 and its two-hundred day moving average price is $195.74. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The company has a market cap of $162.76 billion, a PE ratio of 41.12, a P/E/G ratio of 2.82 and a beta of 0.76.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%. The company had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $6.12 billion. During the same quarter in the previous year, the firm earned $0.77 EPS. Danaher’s revenue was up 5.5% on a year-over-year basis. Equities analysts predict that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be paid a dividend of $0.40 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 annualized dividend and a yield of 0.7%. Danaher’s payout ratio is presently 28.42%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on DHR shares. TD Cowen lifted their price target on shares of Danaher from $236.00 to $255.00 and gave the company a “buy” rating in a research report on Tuesday. Morgan Stanley increased their price target on Danaher from $220.00 to $240.00 and gave the stock an “overweight” rating in a research report on Monday. Barclays raised their price objective on Danaher from $230.00 to $255.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $240.00 price objective on shares of Danaher in a report on Wednesday, July 22nd. Finally, UBS Group began coverage on Danaher in a research report on Wednesday, September 9th. They set a “buy” rating and a $250.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, Danaher presently has an average rating of “Moderate Buy” and a consensus target price of $235.41.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.